Thrivent Financial for Lutherans Buys 11,698 Shares of Patterson Companies, Inc. (NASDAQ:PDCO)

Thrivent Financial for Lutherans increased its stake in Patterson Companies, Inc. (NASDAQ:PDCO) by 18.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,462 shares of the company’s stock after buying an additional 11,698 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.08% of Patterson Companies worth $2,143,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC acquired a new position in Patterson Companies during the third quarter worth approximately $536,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Patterson Companies by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,554,566 shares of the company’s stock worth $33,952,000 after acquiring an additional 81,524 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Patterson Companies by 31.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 33,257 shares of the company’s stock worth $726,000 after acquiring an additional 7,969 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in Patterson Companies in the 3rd quarter valued at $219,000. Finally, Verition Fund Management LLC lifted its holdings in Patterson Companies by 26.9% during the 3rd quarter. Verition Fund Management LLC now owns 59,527 shares of the company’s stock valued at $1,300,000 after purchasing an additional 12,633 shares during the last quarter. 85.43% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PDCO shares. Robert W. Baird upped their price objective on shares of Patterson Companies from $25.00 to $31.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. Mizuho began coverage on shares of Patterson Companies in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $23.00 price target on the stock. Piper Sandler cut their price objective on shares of Patterson Companies from $26.00 to $24.00 and set a “neutral” rating for the company in a research report on Friday, December 6th. Morgan Stanley boosted their price objective on Patterson Companies from $27.00 to $31.35 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Finally, Leerink Partners reiterated a “market perform” rating and set a $31.35 target price (up previously from $29.00) on shares of Patterson Companies in a research note on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $26.57.

Patterson Companies Stock Performance

NASDAQ:PDCO opened at $31.21 on Friday. The company has a market cap of $2.76 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 2.71 and a beta of 0.99. Patterson Companies, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $31.79. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.76 and a current ratio of 1.37. The stock has a fifty day moving average price of $31.08 and a 200-day moving average price of $26.51.

About Patterson Companies

Patterson Companies, Inc engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems.